- 50 Downloads
An event is serious (based on the ICH definition) when the patient outcome is:
* congenital anomaly
* other medically important event
A case series described three women and a man aged 50−72 years, who developed pneumonitis following the administration of bleomycin, carmustine, etoposide, cytarabine, melphalan, pembrolizumab or rituximab [routes, not all durations of dosages, treatment to reactions onsets stated].
Patient 1: A 50-year-old woman, who had stage IV primary mediastinal B-cell lymphoma, started receiving treatment with pembrolizumab 200mg every three weeks. Her previous treatments included the REPOCH regimen comprising rituximab, etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin, the R-DHAP regimen including rituximab, dexamethasone, cytarabine and cisplatin, and palliative radiotherapy. At 12 weeks following the initiation of pembrolizumab, she developed cough, wheezing and...